ONTEEYA

Serial Number 97198619
602

Registration Progress

Application Filed
Dec 31, 2021
Under Examination
Approved for Publication
Published for Opposition
Registered

Trademark Image

ONTEEYA

Basic Information

Serial Number
97198619
Filing Date
December 31, 2021
Abandonment Date
November 3, 2023
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
602
Status Date
Nov 16, 2023
Classes
005

Rights Holder

Fresenius Kabi Deutschland GmbH

16
Address
Else-Kroener-Str. 1
Bad Homburg 61352
DE

Ownership History

Fresenius Kabi Deutschland GmbH

Original Applicant
16
Bad Homburg DE

Legal Representation

Attorney
Scott D. Woldow

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

14 events
Date Code Type Description Documents
Nov 16, 2023 ABN2 O ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Loading...
Nov 16, 2023 MAB2 O ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND Loading...
Nov 16, 2023 MAB2 E ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND Loading...
Aug 2, 2023 CNRT R NON-FINAL ACTION WRITTEN Loading...
Aug 2, 2023 GNRT O NON-FINAL ACTION E-MAILED Loading...
Aug 2, 2023 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Aug 1, 2023 RCCK S SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Loading...
Jan 18, 2023 RCSC S REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED Loading...
Jul 7, 2022 CNSL R SUSPENSION LETTER WRITTEN Loading...
Jul 7, 2022 GNSL F LETTER OF SUSPENSION E-MAILED Loading...
Jul 7, 2022 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Loading...
Jul 5, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Jan 5, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jan 4, 2022 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for human use for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections; pharmaceutical preparations for the treatment of CAR T-cell induced cytokine release syndrome
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005